- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Life Imaging finishes 3-D prototype
Three-dimensional ultrasound developer Life Imaging Systems continues to reach milestones in its relationship with B-K Medical of Copenhagen, Denmark. Life Imaging has developed a prototype that integrates Life's 3-D technology with B-K's ultrasound
Three-dimensional ultrasound developer Life Imaging Systems continues to reach milestones in its relationship with B-K Medical of Copenhagen, Denmark. Life Imaging has developed a prototype that integrates Life's 3-D technology with B-K's ultrasound scanners and transducers. The resulting product allows one system to feature 2-D capabilities with 3-D reconstruction and visualization, according to Life Imaging, based in London, Ontario.
Life plans to deliver the first version of the system to B-K at the beginning of April. Under the terms of the October 1997 agreement signed between the two firms, B-K has worldwide rights to market the technology, which is targeted primarily at urology and surgical applications, according to Life.
With these kinds of collaborative relationships with ultrasound vendors, Life expects to experience substantial revenue growth. The company anticipates sales of $4.5 million (Canadian) in 1999.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI Have an Impact with Fertility-Sparing Treatments for Endometrial and Cervical Cancers?
January 9th 2025In a literature review that includes insights from recently issued guidelines from multiple European medical societies, researchers discuss the role of magnetic resonance imaging (MRI) in facilitating appropriate patient selection for fertility-sparing treatments to address early-stage endometrial and cervical cancer.
